Navigation Links
Lotus Pharmaceuticals, Inc.'s New Drug Laevo-Bambutero Begins Evaluation for Clinical Trials
Date:9/25/2008

BEIJING, Sept. 25 /Xinhua-PRNewswire-FirstCall/ -- Lotus Pharmaceuticals, Inc. (OTC Bulletin Board: LTUS) ("Lotus" or the "Company"), a pharmaceutical products developer, manufacturer and distributor in the People's Republic of China ("PRC"), today announced that China's State Food and Drug Administration (SFDA) is evaluating the Company's drug Laevo-Bambutero for clinical trials.

Laevo-Bambutero is a drug used to treat asthma, and the Company views it as a more effective drug than a number of alternative drugs currently on the market. Lotus obtained the patent along with exclusive production rights in China for Laevo-Bambutero through a technology transfer agreement with Dongguan Kaifa Biomedicine, Inc. in May 2008.

The Company received formal notice from the SFDA that it has started to evaluate Laevo-Bambutero for clinical trials. This evaluation is expected to take from six to nine months and will determine if and when stringent clinical trials begin. If approved, those clinical trials should take approximately eighteen months. Pending final approval for manufacturing and distribution from the SFDA, Lotus plans to launch sales of Laevo-Bambutero by 2012.

"The news from the SFDA is an important first step of many steps needed for bringing Laevo-Bambutero to market," said Dr. Zhongyi Liu, Chairman, CEO and President of Lotus Pharmaceuticals, Inc. "We are pleased to have reached a new milestone in the commercialization of Laevo-Bambutero, which we look forward to adding to our product portfolio."

About Lotus Pharmaceuticals, Inc.

Lotus Pharmaceuticals, Inc. controls and operates Liangfang Pharmaceutical, Ltd. ("Liangfang") and Enze Jiashi Pharmaceutical, Ltd. ("Enze"), two pharmaceutical companies located in Beijing, China. Together, Liangfang and Enze ("Lotus East") undertake the development, production, marketing and distribution of pharmaceutical products. Lotus East has some of the most advanced pharmaceutical production
'/>"/>

SOURCE Lotus Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine technology :

1. Lotus Pharmaceuticals, Inc. Achieves Significant Milestones in the Development of Isosorbide Mononitrate Sustained Release Tablets
2. Jazz Pharmaceuticals, Inc. Announces Final Patient Has Completed Phase III Clinical Trial of Sodium Oxybate to Treat Fibromyalgia
3. Aegerion Pharmaceuticals, Inc. adds Peter Garrambone to Board of Directors, Secures Additional Capital for Clinical Trials
4. Rib-X Pharmaceuticals, Inc. Announces Recent and Upcoming Presentations at Scientific Conferences
5. Meditrina Pharmaceuticals, Inc. Opens Investigational New Drug (IND) Application for Phase IIb Clinical Trial With MPI-676 in Endometriosis
6. Keryx Biopharmaceuticals, Inc. Announces Phase 2 Results on KRX-0401 (Perifosine) in Patients with Relapsed/Refractory Waldenstroms Macroglobulinemia at the 44th Annual Meeting of the American Society of Clinical Oncology
7. Auxilium Pharmaceuticals, Inc. Announces XIAFLEX(TM) Meets Primary Endpoint With Statistical Significance (p<0.001) in CORD I Pivotal Phase III Study for Dupuytrens Contracture
8. Keryx Biopharmaceuticals, Inc. Announces Poster Presentation Highlighting Observed Clinical Activity of KRX-0401 (Perifosine) at the American Society of Clinical Oncology Meeting in Chicago, Illinois
9. Jazz Pharmaceuticals, Inc. Completes Enrollment in First of Two Phase III Clinical Trials of Sodium Oxybate to Treat Fibromyalgia
10. Arena Pharmaceuticals, Inc. Announces Initiation of Phase 1 Clinical Trial of Drug Candidate Under Partnership with Taisho Pharmaceutical Co., Ltd.
11. Alseres Pharmaceuticals, Inc. to Address a Congressional Briefing on Paralysis Research and the Spinal Cord Injury Community at Working 2 Walk in Washington, DC, April 13-15, 2008
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:Reportlinker Adds Bulk Paclitaxel - A Global Update of Market Trends & Opportunities 2Reportlinker Adds Bulk Paclitaxel - A Global Update of Market Trends & Opportunities 3Reportlinker Adds Bulk Paclitaxel - A Global Update of Market Trends & Opportunities 4Reportlinker Adds Bulk Paclitaxel - A Global Update of Market Trends & Opportunities 5Reportlinker Adds Trauma Devices - Trends & Opportunities Worldwide 2Reportlinker Adds Trauma Devices - Trends & Opportunities Worldwide 3Reportlinker Adds Trauma Devices - Trends & Opportunities Worldwide 4Reportlinker Adds Trauma Devices - Trends & Opportunities Worldwide 5Reportlinker Adds Trauma Devices - Trends & Opportunities Worldwide 6Reportlinker Adds Trauma Devices - Trends & Opportunities Worldwide 7Reportlinker Adds Trauma Devices - Trends & Opportunities Worldwide 8Reportlinker Adds Trauma Devices - Trends & Opportunities Worldwide 9Reportlinker Adds European Markets for Drug Eluting and Bare Metal Stents 2009 (15 Countries) 2Reportlinker Adds European Markets for Drug Eluting and Bare Metal Stents 2009 (15 Countries) 3Reportlinker Adds European Markets for Drug Eluting and Bare Metal Stents 2009 (15 Countries) 4Reportlinker Adds European Markets for Drug Eluting and Bare Metal Stents 2009 (15 Countries) 5Reportlinker Adds European Markets for Drug Eluting and Bare Metal Stents 2009 (15 Countries) 6Reportlinker Adds European Markets for Drug Eluting and Bare Metal Stents 2009 (15 Countries) 7Fast Forward LLC and Amplimmune Inc Join Forces to Speed New Treatments to People with MS 13684 1Fast Forward LLC and Amplimmune Inc Join Forces to Speed New Treatments to People with MS 13684 2Fast Forward LLC and Amplimmune Inc Join Forces to Speed New Treatments to People with MS 13684 3Fast Forward LLC and Amplimmune Inc Join Forces to Speed New Treatments to People with MS 13684 4New Survey Takes Important Step in Defining Comprehensive Spine Programs 55275 1New Survey Takes Important Step in Defining Comprehensive Spine Programs 55275 2Just in Time for Allergy Season ZYRTEC 28R 29 Provides New Solutions for Adults and Children 55272 1Just in Time for Allergy Season ZYRTEC 28R 29 Provides New Solutions for Adults and Children 55272 2Just in Time for Allergy Season ZYRTEC 28R 29 Provides New Solutions for Adults and Children 55272 3Just in Time for Allergy Season ZYRTEC 28R 29 Provides New Solutions for Adults and Children 55272 4